These Could also be A number of the High CBD Skincare Shares to Contemplate for 2022

The global CBD skin care market is booming. According to Grand View Research, the market was valued at $ 234.1 million in 2018 and is expected to grow at an annual growth rate of 32.9% from 2019 to 2025. That’s a powerful catalyst for companies like Ayurcann Holdings Corp. (CSE: AYUR) (FSE: 3ZQ0), The Valens company (TSX: VLNS) (OTC: VLNCF), Auxly Cannabis Group Inc. (OTC: CBWTF) (TSX: XLY), Tilray Inc. (NASDAQ: TLRY), Medipharm Labs Corporation (OTC: MEDIF) (TSX: LABS). In addition, Grand View Research notes, “CBD is considered safe and effective for all skin types, but is particularly useful for people struggling with sensitivity, inflammatory conditions, acne and dryness related to the skin. Because of these powerful inflammatory properties, CBD helps the skin’s natural healing process and shortens the lifespan of pimples and eczema. CBD also shows potential antioxidant properties that can help counteract signs of aging. It can even help relieve pain caused by inflammatory skin conditions. “

Ayurcann Holdings Corp. enters Canada’s largest market with the topical skin care line

Ayurcann Holdings Corp., a Canadian extraction company that specializes in processing cannabis and hemp to produce oils and various derivatives, is pleased to announce the launch of its highly potent THC and CBD infused topical skin care line; GLOW. Ayurcann will launch its GLOW line of products through the Ontario Cannabis Store. Products will be made available to adults through additional channels including provincial retailers and storefronts across Ontario.

At the beginning, Ayurcann will bring the combination pack day cream and night cream from GLOW onto the market. The product’s quick-absorbing formula acts quickly to improve application to the areas. GLOW’s non-psychoactive formula harnesses the power of the cannabis plant and uses both THC and CBD mixed with high quality natural botanicals and essential oils.

The first product launch includes two SKUs: GLOW Day Cream and GLOW Night Cream. The GLOW day cream contains a total of 1000 mg of CBD, while the night cream contains a mixture of 500 mg of THC and 500 mg of CBD. With the launch of one of the highest concentrations of active cannabinoids on the market in a topical format, Ayurcann’s strategy is to expand the market share in extracts and extract derivatives while offering consumers exceptional products. Because of its premium quality and value-based price, GLOW is poised to be a first choice among consumers entering the cannabis space in search of the latest products. In a 2021 report on Canadian cannabis users, Deloitte found that nearly half of new users prefer more pure CBD products, with 34% of existing consumers citing general health and well-being as the driver of CBD use.

“We are very pleased to announce GLOW’s first entry into the Canadian market through the OCS, where we are optimistic about its market potential as an industry-leading line of cannabinoid-based topical products. We were pleasantly surprised by the initial interest from consumers and retailers in these products and believe they will help set the standard for cannabinoid-based topicals, ”said Igal Sudman, CEO of Ayurcann.

Other related developments around the markets are:

The Valens company and Citizen Stash Cannabis Corp. are pleased to announce the successful completion of the previously announced agreement plan whereby Valens has acquired all of Citizen Stash’s issued and outstanding common stock and other securities in an all-share transaction effective November 8, 2021, under the terms of the agreement Citizen Stash shareholders are entitled to 0.1620 of one Valens common share for each Citizen Stash common share held.

Auxly Cannabis Group Inc., a leading consumer goods company in the cannabis products market, is pleased to announce the addition of Murray McGowan, Imperial Chief Strategy and Development Officer, to its board of directors in connection with its strategic partnership with Imperial Brands PLC. effective November 1, 2021. Mr. McGowan will join the Auxly Board of Directors as Imperial’s agent, replacing former Imperial nominee Conrad Tate. Mr. Tate has left Imperial but has agreed to remain on the Auxly Board of Directors as an independent director at the Company’s request and will continue to serve on Auxly’s Audit Committee and Compensation Committee. Mr. McGowan was also appointed to the company’s audit committee. Following the appointment of Mr. McGowan, the board of directors will consist of six directors.

Tilray Inc. announced that two of its leading brands, SweetWater Brewing Company and RIFF Cannabis, collaborated on the exclusive US launch of SweetWater RIFF – SweetWater’s first ready-to-drink (RTD) cocktail and its first entry into the spirits category. SweetWater RIFF brings a unique twist to RTD vodka sodas in two offerings: SweetWater RIFF Citrus and SweetWater RIFF Strawberry Mule. “SweetWater’s entry into the spirits category reflects the essence of the SweetWater brand: original, compelling and enticing,” said Brian Miesieski, SweetWater’s chief marketing officer. “SweetWater RIFF delivers a great tasting ready-to-drink cocktail with a premium flavor that has been developed in collaboration with RIFF’s own highly curated, expert approach. We are incredibly excited to expand and create something that is a great alternative to our incredible range of beers and sellers. “

Medipharm Labs Corporation A precision cannabinoid pharmaceutical company, is pleased to announce that Bryan Howcroft is joining MediPharm Labs as Chief Executive Officer and Director effective November 15, 2021. Bryan Howcroft has over 20 years of leadership experience in a variety of industries including medical devices, healthcare imaging, and manufacturing. Most recently, Bryan served as Chief Operational Officer and Chief Financial Officer of Southmedic, a company that provides healthcare products, custom manufacturing and distribution in over 60 countries worldwide. Bryan’s previous experience makes him an ideal leadership position in the international cannabis industry as the healthcare sector, like cannabis, is highly regulated and requires expertise in dealing with complex global regulatory regimes, including the U.S. FDA, and country-specific regulations for medical distribution. Bryan’s tenure at Southmedic included an extremely significant scale of the business to a multi-site operation. Southmedic is recognized as one of Canada’s largest privately held medical device companies.

Disclaimer / Except for the historical information contained herein, the matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results, performance or accomplishments expressed therein statements are implied. Winning Media is not registered with any financial or securities regulator and does not provide investment advice or recommendations to readers of this press release. In order to make specific investment decisions, readers should seek advice for themselves. Winning Media is only remunerated for its services in the form of cash. Under an agreement, Winning Media received from Ayurcann Holdings Corp. three thousand five hundred dollars in advertising and marketing services for Ayurcann Holdings Corp. We own ZERO shares in Ayurcann Holdings Corp.. Please click here for the full disclaimer.

Contact information:
[email protected]